Liposomal amphotericin B

Nenad Macesic, Neil R.H. Stone, John R. Wingard

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

Abstract

The widespread use of amphotericin B deoxycholate (DAmB) is limited because of both infusional toxicity and nephrotoxicity. These inherent limitations were the primary motivation to develop lipid formulations of AmB that are safer, but still retain potent antifungal activity. Liposomal amphotericin B consists of true liposomes that are approximately 80 nm in diameter, that contain various lipids and the amphipathic amphotericin B embedded in the wall of the liposome. Liposomal amphotericin B (LAmB) is widely available and has an extensive usage and safety database (Figure 142.1).

Original languageEnglish
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
PublisherCRC Press
Pages2612-2627
Number of pages16
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
Publication statusPublished - 1 Jan 2017
Externally publishedYes

Cite this

Macesic, N., Stone, N. R. H., & Wingard, J. R. (2017). Liposomal amphotericin B. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 2612-2627). CRC Press.